This report is an updated version of the report published on 29th April 2022 at 08:22 AM GMT+1.

Phoenix Group Holdings PLC
Phoenix Group Holdings PLC (LON: PHNX) is an FTSE 100 listed entity that is engaged in insurance services. It is also engaged in the long-term savings and retirement business.
Investment Rationale for Valuation – Buy at GBX 604.40
Key Risks
Financial Highlights (for the year ended 31 December 2021, as of 14 March 2022)

(Source: Company Website)
One Year Share Price Chart

(Source: REFINITIV; Analysis done by Kalkine Group)
Valuation Methodology: Price/Earnings Approach (FY22E)

*Peers: Few peers considered are Direct Line Insurance Group PLC, Aviva PLC and Beazley PLC.
*All selected peers are LSE-listed Companies from the Financials sector.
Conclusion
The management seems to be positive on delivering both organic as well as inorganic growth going forward, driven by a clear and differentiated strategy making use of important market trends.
Based on the strong cash generation, decent solvency, organic growth and support from the valuation as done using the above method, we have given a “Buy” recommendation on Phoenix Group Holdings PLC at the closing market price of GBX 604.40 (as of 28 April 2022) with lower double-digit upside potential based on 9.31x Price/NTM Earnings (approx.) on FY22E earnings per share (approx.).
Please note markets are trading in a highly volatile zone currently due to certain macro-economic and geopolitical tensions prevailing. Therefore, it is prudent to follow a cautious approach while investing.

Dr. Martens PLC
Dr. Martens PLC (LON: DOCS) is an FTSE 250 listed UK-based leading footwear brand. The Company has a diverse range of product categories such as Originals, Fusion, Kids, Casual and Accessories.
On 1 June 2022, DOCS expects to release its FY22 results.
Investment Rationale – Buy at GBX 210.40
Risk Assessments
Trading Statement (for the three months ended 31 December 2021, as of 27 January 2022)

(Source: Company Filings)
One Year Share Price Chart

(Source: Refinitiv, chart created by Kalkine Group)
Valuation Methodology: Price/Earnings Approach (FY22E)

*Peers: JD Sports Fashion PLC, Burberry Group PLC, and Dunelm Group PLC.
*All selected peers are LSE-Listed Companies from the Consumer Discretionary sector.
Conclusion
Please note markets are trading in a highly volatile zone currently due to certain macro-economic and geopolitical tensions prevailing. Therefore, it is prudent to follow a cautious approach while investing.
Based on strong Q3 FY22 trading update, rebounded UK Retail sales, favourable technical indicators, and support from the valuation as done using the above method, we have given a “BUY” recommendation on Dr. Martens PLC at the closing market price of GBX 210.40 (as on 28 March 2022), with lower double-digit upside potential based on 13.03x Price/NTM Earnings per share (approx.) on FY23E earnings per share (approx.).

Paragon Banking Group PLC
Paragon Banking Group PLC (LON: PAG) is an FTSE 250 listed bank and its products include mortgages for landlords and loans for business customers.
Investment Rationale for Valuation – Buy at GBX 492.80
Key Risks
Financial Highlights (for the year ended 30 September 2021, as of 07 December 2021)

(Source: Company Website)
One Year Share Price Chart

(Source: REFINITIV; Analysis done by Kalkine Group)
Valuation Methodology: Price/Earnings Approach (FY23E)

*Peers: Few peers considered are Close Brothers Group PLC, Natwest Group PLC and Lendinvest PLC.
*All selected peers are LSE-listed Companies from the Financials sector.
Conclusion
The company has maintained the growth momentum in Q1FY22 and delivered an improvement in margins and capital strength.
Based on the impressive performance, expansion in the balance sheet, improvement in margins and support from the valuation as done using the above method, we have given a “Buy” recommendation on Paragon Banking Group PLC at the closing market price of GBX 492.80 (as of 28 April 2022) with lower double-digit upside potential based on 8.70x Price/NTM Earnings (approx.) on FY23E earnings per share (approx.).
Please note markets are trading in a highly volatile zone currently due to certain macro-economic and geopolitical tensions prevailing. Therefore, it is prudent to follow a cautious approach while investing.

Note 1: The reference data in this report has been partly sourced from REFINITIV.
Note 2: Investment decision should be made depending on the investors’ appetite on upside potential, risks, holding duration, and any previous holdings. Investors can consider exiting from the stock if the Target Price mentioned as per the Valuation has been achieved and subject to the factors discussed above.
Note 3: Dividend Yield may vary as per the stock price movement.
Note 4: Target Price refers to a price level which the stock is expected to reach as per the relative valuation method and or technical analysis taking into consideration both short-term and long-term scenarios.
Note 5: ‘Kalkine reports are prepared based on the stock prices captured either from the London Stock Exchange (LSE) and or REFINITIV. Typically, both sources (LSE and or REFINITIV) may reflect stock prices with a delay which could be a lag of 15-20 minutes. There can be no assurance that future results or events will be consistent with the information provided in the report. The information is subject to change without any prior notice.’
Technical Indicators Defined: -
Support: A level where-in the stock prices tend to find support if they are falling, and downtrend may take a pause backed by demand or buying interest.
Resistance: A level where-in the stock prices tend to find resistance when they are rising, and uptrend may take a pause due to profit booking or selling interest.
Stop-loss: It is a level to protect further losses in case of unfavorable movement in the stock prices.
Disclaimer
References to ‘Kalkine’, ‘we’, ‘our’ and ‘us’ refer to Kalkine Limited.
This website is a service of Kalkine Limited. Kalkine Limited is a private limited company, incorporated in England and Wales with registration number 07903332. Kalkine Limited is authorised and regulated by the Financial Conduct Authority under reference number 579414.
The article has been prepared for informational purposes only and is not intended to be used as a complete source of information on any particular company. No advice or information, whether oral or written, obtained by you from Kalkine or through or from the service shall create any warranty not expressly stated. Kalkine does not intend to exclude any liability which it is not permitted to exclude under applicable law or regulation.
Kalkine does not offer financial advice based upon your personal financial situation or goals, and we shall NOT be held liable for any investment or trading losses you may incur by using the opinions expressed in our publications, market updates, news alerts and corporate profiles. Kalkine does not intend to exclude any liability which it is not permitted to exclude under applicable law or regulation. Kalkine’s non-personalised advice does not in any way endorse or recommend individuals, investment products or services for your personal financial situation. You should discuss your portfolios and the risk tolerance level appropriate for your personal financial situation, with a professional authorised financial planner and adviser. You should be aware that the value of any investment and the income from it can go down as well as up and you may not get back the amount invested.
Kalkine Media Limited, an affiliate of Kalkine Limited, may have received, or be entitled to receive, financial consideration in connection with providing information about certain entity(s) covered on its website.
Past performance is not a reliable indicator of future performance.